Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33189
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRobert, Caroline-
dc.contributor.authorCarlino, Matteo S-
dc.contributor.authorMcNeil, Catriona-
dc.contributor.authorRibas, Antoni-
dc.contributor.authorGrob, Jean-Jacques-
dc.contributor.authorSchachter, Jacob-
dc.contributor.authorNyakas, Marta-
dc.contributor.authorKee, Damien-
dc.contributor.authorPetrella, Teresa M-
dc.contributor.authorBlaustein, Arnold-
dc.contributor.authorLotem, Michal-
dc.contributor.authorArance, Ana-
dc.contributor.authorDaud, Adil I-
dc.contributor.authorHamid, Omid-
dc.contributor.authorLarkin, James-
dc.contributor.authorAnderson, James-
dc.contributor.authorKrepler, Clemens-
dc.contributor.authorGrebennik, Dmitri-
dc.contributor.authorLong, Georgina V-
dc.date2023-
dc.date.accessioned2023-06-30T06:19:34Z-
dc.date.available2023-06-30T06:19:34Z-
dc.date.issued2023-08-20-
dc.identifier.citationJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2023-08-20; 41(24)en_US
dc.identifier.issn1527-7755-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33189-
dc.description.abstractClinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Immune checkpoint inhibitors have led to unprecedented prolongation of overall survival (OS) for patients with advanced melanoma. Five-year follow-up of KEYNOTE-006 showed pembrolizumab prolonged survival versus ipilimumab. Efficacy results with 7-year follow-up are presented. At data cutoff (April 19, 2021), median follow-up was 85.3 months (range, 0.03-90.8 months). Median OS was 32.7 months for pembrolizumab versus 15.9 months for ipilimumab (hazard ratio [HR], 0.70; 95% CI, 0.58 to 0.83); 7-year OS was 37.8% and 25.3%, respectively. OS HRs favored pembrolizumab regardless of BRAF status or prior BRAF/MEK-inhibitor treatment and prognostic characteristics (elevated lactate dehydrogenase, large tumor size, and brain metastasis). Median modified progression-free survival (mPFS) was 9.4 months for pembrolizumab versus 3.8 months for ipilimumab; 7-year mPFS was 23.8% and 13.3%, respectively. In patients who completed ≥94 weeks of pembrolizumab, the 5-year OS was 92.9% and the 5-year mPFS was 70.1%. The objective response rate with second-course pembrolizumab (n = 16) was 56% (95% CI, 30 to 80) and the 2-year mPFS was 62.5%. These findings confirm that pembrolizumab provides long-term survival benefit in advanced melanoma.en_US
dc.language.isoeng-
dc.titleSeven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncologyen_US
dc.identifier.affiliationGustave Roussy and Paris-Saclay University, Villejuif, France.en_US
dc.identifier.affiliationMelanoma Institute Australia, The University of Sydney, Westmead and Blacktown Hospitals, Sydney, NSW, Australia.en_US
dc.identifier.affiliationChris O'Brien Lifehouse, Camperdown, NSW, Australia.en_US
dc.identifier.affiliationJonsson Comprehensive Cancer Center at The University of California, Los Angeles (UCLA), Los Angeles, CA.en_US
dc.identifier.affiliationAix-Marseille University, Hospital of the Timone, Marseille, France.en_US
dc.identifier.affiliationSheba Medical Center-Tel HaShomer, Ramat Gan, Israel.en_US
dc.identifier.affiliationOslo University Hospital, Oslo, Norway.en_US
dc.identifier.affiliationAustin Healthen_US
dc.identifier.affiliationSunnybrook Health Sciences Centre, Toronto, ON, Canada.en_US
dc.identifier.affiliationMount Sinai Medical Center Comprehensive Cancer Center, Miami Beach, FL.en_US
dc.identifier.affiliationSharett Institute of Oncology, Hadassah University Hospital Ein Kerem, Jerusalem, Israel.en_US
dc.identifier.affiliationHospital Clinic Barcelona and IDIBAPS, Barcelona, Spain.en_US
dc.identifier.affiliationUCSF, San Francisco, CA.en_US
dc.identifier.affiliationThe Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA.en_US
dc.identifier.affiliationThe Royal Marsden NHS Foundation Trust, London, United Kingdom.en_US
dc.identifier.affiliationMerck & Co, Inc, Rahway, NJ.en_US
dc.identifier.affiliationMelanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.en_US
dc.identifier.doi10.1200/JCO.22.01599en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-9493-0238en_US
dc.identifier.orcid0000-0003-3669-8458en_US
dc.identifier.orcid0000-0002-0667-153Xen_US
dc.identifier.orcid0000-0001-6331-3440en_US
dc.identifier.orcid0000-0002-4685-1666en_US
dc.identifier.orcid0000-0003-1703-8008en_US
dc.identifier.orcid0000-0002-6617-8421en_US
dc.identifier.orcid0000-0002-8238-4655en_US
dc.identifier.orcid0000-0001-5569-9523en_US
dc.identifier.orcid0000-0001-8894-3545en_US
dc.identifier.pubmedid37348035-
dc.description.startpageJCO2201599-
local.name.researcherKee, Damien-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptMedical Oncology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

20
checked on Feb 29, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.